July 22, 2020
Patent examination ongoing in Korea, USA, Europe, China, India etc.
Bukwang Pharmaceutical (“Bukwang”) announced that its...
June 30, 2020
Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financin...
June 8, 2020
Midazolam export to Luxembourg and France completed, the United Kingdom and Chile under discussion
Bukwang announced that...
March 10, 2020
Levovir demonstrated comparable efficacy to KALETRA® against coronavirus in vitro
Bukwang Pharmaceutical Co., Ltd. announ...
February 14, 2020
- Contera Pharma is preparing for public offering in KOSDAQ -
Bukwang has recently received the investigational new drug...
January 31, 2020
- Kalbe International to take on sales in 2 approved countries
Bukwang Pharmaceutical Co., Ltd (Bukwang) announced that i...
January 10, 2020
Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 s...
January 2, 2020
Bukwang Pharmaceutical announced that it has entered into an agreement with Sanofi-Aventis Korea to co-promote an ARB cl...
November 13, 2019
ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseas...
September 30, 2019
ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up...
Older Posts >
Dyna Therapeutics, subsidiary of Bukwang, registered patent of anticancer drug SOL-804 in Japan
Contera Pharma, subsidiary of Bukwang, raised 51 billion KRW in Series B financing round
Bukwang exports hipnotic-sedative emergency drug for COVID-19 related treatment
Bukwang’s antiviral drug, Levovir®, confirms antiviral effect against coronavirus
Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND
Bukwang Initiates Exportation of its
In-House-Developed Drug, DEXIDⓇ to Southeast Asia
Bukwang initiates dosing of JM-010 in Europe phase 2 study
Bukwang Pharmaceutical has entered into co-promotion agreement with Sanofi- Aventis Korea on AprovelⓇ product family
ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
ASLAN PHARMACEUTICALS AND BUKWANG PHARMACEUTICAL ESTABLISH A JOINT VENTURE, JAGUAHR THERAPEUTICS, TO DEVELOP NOVEL IMMUNO-ONCOLOGY THERAPIES